Seattle Genetics to halt late-stage study of leukemia drug


Shutterstock photo

June 19 (Reuters) - U.S. drug developer Seattle Genetics Inc
<SGEN.O> said on Monday it would discontinue a late-stage study
of its drug to treat older patients with acute myeloid leukemia
due to safety concerns.
    The trial data showed a higher rate of deaths in patients
who took the drug, vadastuximab talirine, compared to those on a
placebo, the company said. [nBw1X7kYca]

 (Reporting by Akankshita Mukhopadhyay in Bengaluru; Editing by
Sai Sachin Ravikumar)
 ((Akankshita.Mukhopadhyay@thomsonreuters.com; within U.S. +1
646 223 8780, outside U.S. +91 80 6749 0010; ; Reuters
Messaging:
akankshita.mukhopadhyay.thomsonreuters.com@reuters.net))

Keywords: SEATTLE GENETICS STUDY/ (URGENT)



This article appears in: World Markets , Stocks , Technology
Referenced Symbols: SGEN


More from Reuters

Subscribe






See headlines for SGEN

Follow on:








Research Brokers before you trade

Want to trade FX?